1. Fractional flow reserve derived from computed tomography coronary angiography in the assessment of stable chest pain. The FORECAST Randomised Trial
- Author
-
Mark A. Hlatky, Colin Berry, Camilla Barrett, Lucy Johnson, Ian Ford, Mamas A. Mamas, James Shambrook, Sam Wilding, Gerry P McCann, Anoop Chauhan, Kayleigh Hill, Justin Carter, Darran Ball, Jacqui Nuttall, Neal G. Uren, Beth Stuart, Zoe Nicholas, Kim Fox, Peter O'Kane, Ronak Rajani, Carl Roobottom, Derek L. Connolly, Alex Hobson, Zina Eminton, Nick Curzen, and Pamela S. Douglas
- Subjects
Fractional flow reserve (FFRCT) ,Stable angina ,Computed Tomography Angiography ,Coronary Artery Disease ,Fractional flow reserve ,030204 cardiovascular system & hematology ,Chest pain ,Coronary Angiography ,Computed tomography coronary angiography ,law.invention ,Coronary artery disease ,Angina ,0302 clinical medicine ,Randomized controlled trial ,law ,Clinical endpoint ,AcademicSubjects/MED00200 ,030212 general & internal medicine ,1102 Cardiorespiratory Medicine and Haematology ,medicine.diagnostic_test ,Heart ,Coronary Vessels ,Plaque, Atherosclerotic ,Fractional Flow Reserve, Myocardial ,Cardiology ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,Quality of life ,medicine.medical_specialty ,Ischaemic Heart Disease ,03 medical and health sciences ,Predictive Value of Tests ,Clinical Research ,Internal medicine ,medicine ,Cost analysis ,Humans ,Myocardial ,Angina, Stable ,Surrogate endpoint ,business.industry ,Coronary Stenosis ,1103 Clinical Sciences ,medicine.disease ,R1 ,Cardiovascular System & Hematology ,Angiography ,business ,Tomography, X-Ray Computed - Abstract
Aims Fractional flow reserve (FFRCT) using computed tomography coronary angiography (CTCA) determines both the presence of coronary artery disease and vessel-specific ischaemia. We tested whether an evaluation strategy based on FFRCT would improve economic and clinical outcomes compared with standard care. Methods and results Overall, 1400 patients with stable chest pain in 11 centres were randomized to initial testing with CTCA with selective FFRCT (experimental group) or standard clinical care pathways (standard group). The primary endpoint was total cardiac costs at 9 months. Secondary endpoints were angina status, quality of life, major adverse cardiac and cerebrovascular events, and use of invasive coronary angiography. Randomized groups were similar at baseline. Most patients had an initial CTCA: 439 (63%) in the standard group vs. 674 (96%) in the experimental group, 254 of whom (38%) underwent FFRCT. Mean total cardiac costs were higher by £114 (+8%) in the experimental group, with a 95% confidence interval from −£112 (−8%) to +£337 (+23%), though the difference was not significant (P = 0.10). Major adverse cardiac and cerebrovascular events did not differ significantly (10.2% in the experimental group vs. 10.6% in the standard group) and angina and quality of life improved to a similar degree over follow-up in both randomized groups. Invasive angiography was reduced significantly in the experimental group (19% vs. 25%, P = 0.01). Conclusion A strategy of CTCA with selective FFRCT in patients with stable angina did not differ significantly from standard clinical care pathways in cost or clinical outcomes, but did reduce the use of invasive coronary angiography., Graphical Abstract Summarising trial design and main results.
- Published
- 2021